Venlafaxine in the Treatment of Premenstrual Dysphoric Disorder

  title={Venlafaxine in the Treatment of Premenstrual Dysphoric Disorder},
  author={Ellen W. Freeman and Karl E. Rickels and Kimberly Ann Yonkers and Nadia R. Kunz and Mary Kay McPherson and Gertrude Virginia Upton},
  journal={Obstetrics \& Gynecology},

Figures and Tables from this paper

Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial.
Duloxetine was effective and generally well tolerated in the treatment of PMDD and significant improvements were demonstrated by secondary measures, including reduction in self-rated functional impairment and improvement in quality of life.
Effective open‐label treatment of premenstrual dysphoric disorder with venlafaxine
  • M. Hsiao, C. Liu
  • Psychology, Medicine
    Psychiatry and clinical neurosciences
  • 2003
It is indicated that venlafaxine is effective in the treatment of ethnic Taiwanese women with PMDD, and patients had significant improvement of the mood and behavior components in the PRISM calendar.
Efficacy and Tolerability of Premenstrual Use of Venlafaxine (Flexible Dose) in the Treatment of Premenstrual Dysphoric Disorder
It is suggested that premenstrual use of venlafaxine is an efficacious and well-tolerated treatment for pre menstrual dysphoric disorder.
Duloxetine for premenstrual dysphoric disorder: a pilot study
Duloxetine 60 mg/day was effective in reducing PMDD symptoms and generally well tolerated and the results appeared to be strong and consistent across measures.
Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder
Fluoxetine is generally a well-tolerated treatment for PMDD and discontinuation effects have not been reported with intermittent dosing regimens.
The pharmacologic management of premenstrual dysphoric disorder
Due to the unique pathophysiology of the disorder, the selective serotonin re-uptake inhibitors can be effectively administered intermittently, with dosing limited to the luteal phase of the cycle (2 weeks prior to menses).
Treatment of Premenstrual Dysphoric Disorder
Treatment of PMDD and severe premenstrual syndrome has centered on neuromodulation via serotonin reuptake inhibitor antidepressants, and ovulation suppression utilizing various contraceptive and hormonal preparations.
Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline
Sertraline (Zoloft™, Pfizer Inc.) is a selective serotonin re-uptake inhibitor (SSRI) which has been approved by the US FDA for the treatment of premenstrual dysphoric disorder (PMDD). PMDD is a


Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder.
Fluoxetine was significantly superior to bupropion and placebo as an effective treatment for PMDD, and patient satisfaction was far greater with fluoxettine.
Fluoxetine in the Treatment of Premenstrual Dysphoria
Symptomatic Improvement of Premenstrual Dysphoric Disorder With Sertraline Treatment: A Randomized Controlled Trial
Serotonin reuptake inhibitors such as sertraline are useful therapeutic options for women with premenstrual dysphoria as reflected by symptomatic improvement and change in reported functional impairment.
Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo‐controlled trial
It is concluded that low doses of clomipramine effectively reduce premenstrual irritability and dysphoria with a response rate close to 100%.
Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study.
Luteal phase treatment with sertraline was a safe and effective treatment for moderate-to-severe premenstrual dysphoric disorder and a repeated-measures analysis of variance for crossover designs found a significant beneficial effect from sERTraline treatment in improving the calendar of pre menstrual experiences.
Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial.
The comparison of 2 classes of antidepressants strongly favored the serotonergic drug, which effectively reduced symptoms and improved functioning and was well tolerated by women with severe premenstrual syndrome.
Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant.
This preliminary randomized, double-blind study compared the responses to half-cycle or full-cycle dosing of sertraline in 31 patients who completed a preceding double- blind, short-term treatment trial for premenstrual syndrome (PMS).
Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome.
Luteal phase treatment in women with dysphoric PMS produced significant improvements in depression, impairment, and global ratings compared with placebo and was equivalent in efficacy to sertraline given during the entire menstrual cycle.
Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial.
This study is the first to demonstrate a significant response to a serotonin selective reuptake inhibitor used only during the luteal phase of the menstrual cycle, and points out the importance of this finding both in terms of economic cost of patients as well as how it may add to the growing understanding of the etiology of PMDD.